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NEMO (NF-B essential modifier)/IKK (IB kinase-)
is required for the activation of the IB kinase complex
(IKK) by inflammatory stimuli such as tumor necrosis
factor (TNF-). Here we show that TNF- stimulates the
ubiquitination of NEMO in a manner that does not ap-
pear to target it for degradation and that is impaired by
mutations in the NEMO zinc finger. Mutations of the
zinc finger are found in patients with hypohidrotic ec-
todermal dysplasia with immunodeficiency (HED-ID)
and lead to the impairment of TNF--stimulated IKK
phosphorylation and activation. In addition, the ubiq-
uitination of NEMO is mediated by c-IAP1, an inhibitor
of apoptosis protein that is a component of the TNF
receptor signaling complex. Thus, the ubiquitination of
NEMO mediated by c-IAP1 likely plays an important
role in the activation of IKK by TNF-. Also, defective
NEMO ubiquitination may be responsible for the im-
paired cellular NF-B signaling found in patients with
HED-ID.
The NF-B/Rel family of transcription factors function in a
wide range of biological activities including inflammation, im-
munity, and apoptosis, and their activities are regulated by
their interactions with IB proteins (1–4). In unstimulated
cells, NF-B is kept inactive in the cytoplasm by virtue of the
masking of its nuclear localization sequence by bound IB
protein. Exposure of cells to proinflammatory stimuli triggers
the activation of a multisubunit IB kinase (IKK)1 complex
that phosphorylates IB proteins on two serine residues (5–7).
Phosphorylation of IB proteins triggers their polyubiquitina-
tion and their subsequent recognition and degradation by the
proteasome. Destruction of IB proteins liberates NF-B to
enter the nucleus and activate gene expression (2, 3, 8).
The predominant IKK complex found in cell lines contains
two catalytic subunits, IKK (or IKK1) and IKK (or IKK2)
(9–13), and a regulatory subunit, NEMO (or IKK) (14–17).
IKK and IKK are serine/threonine protein kinases, whereas
NEMO contains several protein interaction motifs but no ap-
parent catalytic domains. Subunit reconstitution experiments
in yeast and mammalian cells suggest that IKK is composed of
a NEMO homodimer bound together with either an IKK/
IKK heterodimer or an IKK homodimer (18). Although struc-
turally similar, IKK and IKK have distinct cellular func-
tions. IKK phosphorylates IB and is critical for IKK and
NF-B activation in response to proinflammatory stimuli (19–
21). In contrast, IKK phosphorylates the NF-B2/p100 pre-
cursor and stimulates its processing in a fashion that is inde-
pendent of the IKK complex (22). The biochemical mechanisms
underlying the activation of IKK in response to proinflamma-
tory stimuli are not well understood. Although it is known that
phosphorylation of Ser179 and Ser181 in the activation loop of
IKK is required and may be sufficient for IKK activation by
proinflammatory stimuli (12, 23), the biochemical mechanisms
regulating these phosphorylation events are not clear.
NEMO was initially identified by complementation cloning
in a rat cell line in which NF-B could not be activated (16). It
was subsequently also isolated by biochemical purification of
the IKK complex and microsequencing (14, 17). Structural pre-
dictions indicate that NEMO contains several coiled-coil do-
mains, a leucine zipper, and a C-terminal zinc finger. Genetic
studies suggest that NEMO is absolutely required for the ac-
tivation of IKK and NF-B in response to diverse stimuli (16,
24–26). In humans, amorphic mutations in the NEMO gene
that are caused by large genomic deletions are responsible for
familial incontinentia pigmenti (IP) (27) whereas hypomorphic
NEMO mutations are found in patients with hypohidrotic ec-
todermal dysplasia with immunodeficiency (HED-ID) (27–31).
A subset of patients with HED-ID carry mutations in the pre-
dicted zinc finger domain of NEMO and the integrity of this
domain has been shown to be important for full IKK activation
in response to TNF- in murine embryonic fibroblasts (32).
Although it is known that NEMO is required for the formation
of a high molecular weight IKK complex (16), the exact role of
NEMO in IKK activation remains unclear. Because NEMO has
been found to interact with a variety of signaling molecules, it
has been proposed that NEMO may link upstream activators to
the IKK complex (7).
In this report, we identify a role for the NEMO zinc finger in
NEMO ubiquitination. We find that NEMO is ubiquitinated in
response to TNF- in a manner that does not appear to target
it for degradation and that is dependent on an intact zinc
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finger. The inhibitor of apoptosis protein c-IAP1 mediates the
ubiquitination of NEMO in response to TNF- and functions as
an E3 ligase to ubiquitinate NEMO both in vitro and in vivo. In
addition, NEMO proteins containing mutations in the zinc
finger show impaired ubiquitination both by c-IAP1 and in
response to TNF-. These mutants also demonstrate impaired
abilities to rescue TNF--induced IKK activation in a NEMO-
deficient cell line. Our results suggest that NEMO ubiquitina-
tion mediated by c-IAP1 is essential for the proper activation of
the IKK signalsome complex by TNF-.
EXPERIMENTAL PROCEDURES
Cell Culture—HEK 293T and HeLa cells were grown in Dulbecco’s
modified Eagle’s medium (Invitrogen) supplemented with 10% fetal
bovine serum. Jurkat cells and the NEMO mutant JM4.5.2 cell line (gift
of S.-C. Sun) were cultured in RPMI (Invitrogen) supplemented with
10% fetal bovine serum. All cells were grown in a 37 °C incubator with
5% CO2. Transfections of 293T and HeLa cells were performed with
LipofectAMINE (Invitrogen) according to the manufacturer’s instruc-
tions. Transfections of the JM4.5.2 cell line was performed using
DEAE-dextran.
Plasmids—The human NEMO cDNA was PCR amplified from an
IMAGE Consortium expressed sequence tag clone (number 41072) and
inserted into pcDNA3-HA. The ZF (codons 1–392) and C417R (Cys417
mutated to Arg) NEMO mutants were created using standard PCR
procedures. Human ubiquitin (Ub) cDNA were PCR amplified from a
human lymphocyte/leukocyte cDNA library (Clonetech) and subcloned
into pcDNA3-FLAG and pcDNA3-AU1. The Ub 7R, K48R, and G76A
mutants were created by standard PCR procedures. c-IAP1 and XIAP
cDNAs were PCR amplified and subcloned into pcDNA3-FLAG and
pcDNA3-Myc vectors. The 121 (codons 122–618), 321 (codons 322–
618), 1–396 (codons 1–396), RING (codons 1 to 570), C605A (Cys605
mutated to Ala), and RING (codons 562–618) c-IAP1 mutants were
constructed using standard PCR procedures. Mutations were verfied by
automated DNA sequencing (University of Michigan DNA Sequencing
Core).
Immunoprecipitations—For the visualization of endogenous modi-
fied NEMO protein, HeLa cells were lysed in IP lysis buffer (50 mM Tris,
pH 7.6, 250 mM NaCl, 1% Triton X-100, 0.5% Nonidet P-40, 3 mM EGTA,
3 mM EDTA, 10% glycerol, 0.1 mM Na3VO4, 10 M N-ethylmaleimide)
supplemented with a mixture of protease inhibitors (Roche Applied
Science). Lysates were incubated with NEMO antibody and protein
G-Sepharose, and immunoprecipitates were washed four times with IP
lysis buffer and once with IP lysis buffer supplemented with 3 M urea.
All immunoprecipitates were boiled in SDS-PAGE sample buffer and
resolved on a 7.5% polyacrylamide gel. Proteins were transferred to
polyvinylidene difluoride membrane and probed with Ub or NEMO
antibodies. To minimize the detection of the IgG heavy chain, protein A
conjugated to horseradish peroxidase (Zymed Laboratories Inc.) was
used as a secondary antibody for anti-NEMO immunoblots.
For coimmunoprecipitation assays, cells were lysed in EBC150 (50
mM Tris, pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40, 50 mM NaF, 0.1 mM
Na3VO4, 1 mM DTT) supplemented with a mixture of protease inhibi-
tors (Roche Applied Science), and lysates were incubated with the
appropriate antibody for 2 h at 4 °C and with protein G-Sepharose for 1
additional h. All immunoprecipitates were boiled in SDS-PAGE sample
buffer and resolved on a 7.5% polyacrylamide gel.
RNA Interference (RNAi) Knockdown Experiments—For the knock-
down of c-IAP1 expression, we employed a strategy similar to that
described previously (33). An oligonucleotide corresponding to a hairpin
short interfering RNA (siRNA) targeting a unique 19-bp c-IAP1 mRNA
sequence (GGAAAUGCUGCGGCCAACA) was subcloned into pTKO, a
vector that directs the expression of siRNAs driven by the H1 RNA
FIG. 1. NEMO is ubiquitinated in vivo. A, HeLa cells were stimulated with human TNF- (10 ng/ml) for the indicated time periods, and
anti-NEMO immunoprecipitates were probed with NEMO antibody (Santa Cruz Biotechnology, FL-419) as indicated. Both short and long
exposures after immunoblotting with NEMO antibody are shown. Lysates were immunoblotted with phospho-IB (Cell Signaling) and IB
(Santa Cruz Biotechnology, C-21) antibodies. B, HeLa cells were stimulated with TNF- (10 ng/ml) for 5 min where indicated and lysed.
Anti-NEMO immunoprecipitates were probed a monoclonal Ub antibody (Santa Cruz Biotechnology, P4D1) (top) or NEMO antibody (bottom). C,
FLAG-tagged wild-type Ub or Ub (G76A) were coexpressed in 293T cells with HA-NEMO where indicated. Extracts were prepared as described
previously (53) under denaturing conditions and anti-HA (Santa Cruz Biotechnology, Y-11) immunoprecipitates were probed with FLAG M2
antibody (Sigma). D, HA-NEMO or HA-E2F-4 was coexpressed in 293T cells with FLAG-Ub as indicated. Cells were treated with MG132 (10 M)
or carrier (Me2SO) 6 h prior to lysis. Immunoprecipitations were performed as in C and immunoblotting was performed with HA (Covance) or FLAG
M2 antibody.
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promoter and contains a puromycin selection marker.2 One day follow-
ing transfection of 293T cells with pTKO plasmids, transfected cells
were selected for by incubation in media containing puromycin (3 g/
ml) (Sigma) for 72 h. Whole cell lysates were subsequently prepared for
immunoblot or immunoprecipitation analysis.
Ub Conjugation Assays—Ubiquitination reactions were performed in
20-l reactions containing 25 mM Tris (pH 7.5), 50 mM NaCl, 10 mM
MgCl2, 2 mM ATP, and 0.5 mM DTT. Where necessary, rabbit E1
(Boston Biochemical) (40 ng), bovine Ub (Sigma) or His6-tagged Ub (1
g), His6-UbcH5C, or related E2 (0.2 g), GST-c-IAP1 (0.2 g), and
MBP-NEMO (0.1 g), and mutant variants were included. Reactions
were incubated at 30 °C for 1 h, terminated by addition of SDS-PAGE
sample buffer, and separated on 7.5% polyacrylamide gels. Proteins
were transferred to polyvinylidene difluoride membrane and probed
with MBP antibody. AU1-tagged wild-type and mutant Ub cDNAs were
cloned into pET3E-His. Wild-type and mutant NEMO coding sequences
were cloned into pMAL-c2 (New England Biolabs) for expression as
MBP fusion proteins. c-IAP1 wild-type and mutant cDNAs were cloned
into pGEX-KG for expression as GST fusion proteins. GST fusion, MBP
fusion, and His6-tagged proteins were expressed in the Escherichia coli
strain BL21(DE3)RIL (Stratagene), which harbors a helper plasmid
that encodes the AGA-specific ArgU tRNA. His-tagged UbcH3, UbcH6,
UbcH10, UbcH13, and UbcH7 were purchased from Boston
Biochemical.
Retroviral Infections—JM4.5.2 cells stably expressing NEMO pro-
teins were created by retroviral infections. HA-tagged wild-type and
mutant (C417R) NEMO cDNAs were PCR amplified and subcloned into
the retroviral expression vector pPGS-CMV-CITE-neo (gift of G. Nabel).
Amphotropic Phoenix packaging cells (gift of G. Nolan) in 6-well plates
were transfected with 2 g of retroviral expression plasmid using Li-
pofectAMINE 2000 reagent (Invitrogen). 48 h following transfection,
the viral supernatants were supplemented with polybrene (9 mg/ml)
and filtered through a 0.45-m filter. Viral supernatants were incu-
bated with 1  106 JM4.5.2 cells and spun at 1800 rpm for 45 min at
room temperature. Infected cells were resuspended in regular growth
medium containing 1 g/ml G418 (Invitrogen) and stably infected cells
were selected for 1 week.
Kinase Assays—To measure IKK activity, cells were lysed in kinase
lysis buffer (20 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM
EDTA, 30 mM NaF, 2 mM sodium pyrophosphate, 0.1 mM Na3VO4, 1 mM
DTT), and anti-NEMO immunoprecipitates were incubated in 20-l
reactions containing 50 mM Tris (pH 7.5), 10 mM MgCl2, 15 M ATP, 1
mM DTT, 0.5 g GST-IB (1–54), and 5 Ci of [-32P]ATP (ICN) at
30 °C for 20 min. Reactions were terminated by the addition of SDS-
PAGE sample buffer and resolved on a 10% polyacrylamide gel. Pro-
teins were transferred to polyvinylidene difluoride membrane and ex-
posed to x-ray film. GST-IB-(1–54) was purified from DH5 bacteria
transformed with pGEX-IB-(1–54) (gift of M. Karin).
RESULTS AND DISCUSSION
Ubiquitination of NEMO in Cells—An earlier report (34)
described the purification of a multiprotein IB kinase com-
plex that could be activated in vitro by a ubiquitination event.
One possibility is that ubiquitination of IKK may regulate its
activity. To investigate whether IKK may be ubiquitinated
during the course of its activation by TNF-, we immunopre-
cipitated individual IKK subunits from HeLa cells following
stimulation for various time periods. Interestingly, TNF-
treatment induced the accumulation of a ladder of slower mi-
grating forms of NEMO (Fig. 1A). These modifications on
NEMO paralleled the phosphorylation and degradation of
IB. On the other hand, we failed to detect similar modifica-
tion of IKK or IKK under the same conditions (data not
shown). Immunoblotting using an Ub antibody suggested that
TNF- stimulated the modification of NEMO by different num-
bers of Ub molecules (Fig. 1B). NEMO-Ub conjugates were also
detected in transient transfection experiments using 293T cells
in which both epitope-tagged Ub and NEMO were expressed
(Fig. 1C). An “inactive” Ub mutant that contained a substitu-
tion of Ala for the terminal Gly residue (G76A) (35) was unable
to support NEMO ubiquitination.
Because the experiments described above were performed in
the absence of proteasome inhibitor, the NEMO-Ub conjugates
seen in vivo were apparently not targets for immediate destruc-
tion by the proteasome. To examine this idea further, we com-
pared NEMO-Ub conjugates with E2F-4-Ub conjugates, which
are known to be targeted for degradation by the Ub-proteasome
pathway (36). As expected, E2F-4-Ub conjugates were detect-
able only when cells were incubated with a proteosome inhib-
itor (Fig. 1D). In contrast, NEMO-Ub conjugates were readily
visible in the absence of proteasome inhibitor and were only
slightly altered in the presence of proteasome inhibitor. Thus,
the ubiquitination of NEMO may have primarily a regulatory
role, rather than a role in protein stability.
Ubiquitination of NEMO Is Dependent on Its Zinc Finger—
All NEMO orthologs identified to date contain predicted zinc
finger motifs at their extreme C termini (5–7) (Fig. 2A). The
zinc finger has been found to be the frequent target of muta-
tions found in the NEMO gene loci of patients with the congen-
ital disorder HED-ID (27–31). Cells from these patients display
defective NF-B signaling (29, 30). Recently, the zinc finger
was reported to be partially required for IKK activation in
response to TNF- in mouse embryonic fibroblasts (32). We
found, however, that deletion of the zinc finger in NEMO did
not affect its binding to IKK, IKK, RIP, or A20 in coimmu-
nprecipitation assays (data not shown). To test whether the
zinc finger might be important for NEMO ubiquitination, we
examined two NEMO mutants. One mutant contained a dele-
tion of the last 27 residues comprising the predicted zinc finger2 E. D. Tang and K.-L. Guan, manuscript in preparation.
FIG. 2. An intact zinc finger in NEMO is required for ubiquiti-
nation in vivo. A, depicted is an alignment of the sequences of the
predicted zinc fingers found in the C termini of NEMO orthologs from
Homo sapiens (residues 393–419), Mus musculus (residues 386–412),
Xenopus laevis, and Drosophila melanogaster (residues 359–387). The
residues that are conserved in all species are in bold. The position of the
predicted zinc-coordinating residues are indicated by the asterisks. The
arrow indicates the position of Cys417 in human NEMO. The peptide
sequence from X. laevis NEMO was derived from an expressed sequence
tag sequence from a partial cDNA clone and ends with the predicted
terminal residue. GenBankTM accession numbers for the sequences are
6685695 (H. sapiens), 6093481 (M. musculus), 15044130 (X. laevis), and
9937530 (D. melanogaster). B, HA-tagged wild-type and mutant NEMO
proteins were coexpressed in 293T cells with FLAG-Ub as indicated.
Transfected cells were treated with TNF- (10 ng/ml) prior to lysis.
Immunoprecipitations were performed and analyzed as described in the
legend to Fig. 1D.
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(ZF), and another had a substitution of Arg for Cys417 (C417R)
as seen in an HED-ID patient (29–31) (Fig. 2A). Cys417 is one
of the predicted zinc coordinating residues of the zinc finger.
When wild-type and mutant NEMO proteins were coexpressed
with Ub in cells, the ubiquitination of wild-type NEMO was
enhanced by TNF-, as seen with endogenous NEMO (Fig. 2B).
In contrast, the ubiquitination of neither of the two zinc finger
mutants was enhanced by TNF- treatment. An intact zinc
finger in NEMO therefore appears to be necessary for the
stimulation of NEMO ubiquitination by TNF-.
Engagement of tumor necrosis factor receptor 1 (TNFR1) by
TNF- leads to the recruitment of several molecules to the
receptor complex including TRAF2, c-IAP1, and the IKK com-
plex (37–39). TRAF2 and c-IAP1 can both function as E3s (Ub
ligases) via their RING fingers motifs (40–42). E3s function
together with E2s (Ub-conjugating enzymes) to catalyze pro-
tein ubiquitination (43). We examined whether expression of
either of these two Ub ligases could affect NEMO ubiquitina-
tion. Transfection of c-IAP1, but not TRAF2, markedly en-
hanced the levels of NEMO-Ub conjugates without decreasing
the steady-state levels of NEMO (Fig. 3A). Another related
inhibitor of apoptosis protein, XIAP, had a relatively smaller
effect on NEMO ubiquitination. Since the E3 activity of c-IAP1
is dependent on its C-terminal RING finger domain (42), we
examined whether the RING finger was required for c-IAP1 to
enhance NEMO ubiquitination. Deletion of the RING finger
prevented c-IAP1 from enhancing NEMO-Ub conjugates (Fig.
3B). A fragment of c-IAP1 containing the RING finger alone
FIG. 3. c-IAP1 functions as an E3 to ubiquitinate NEMO. A, FLAG-c-IAP1, FLAG-XIAP, and FLAG-TRAF2 were coexpressed in 293T cells
with AU1-Ub and HA-NEMO where indicated. Immunoprecipitations and cell lysates were analyzed as described in the legend to Fig. 1b with HA,
AU1, or FLAG M2 antibody. B, HA-NEMO and various FLAG-tagged c-IAP1 proteins were coexpressed with AU1-Ub in 293T cells as indicated.
Immunoprecipitations were analyzed as described in the legend to A. C, ubiquitination assays were performed with E1, His6-UbcH5C, GST-c-IAP1,
MBP-NEMO, and bovine Ub where indicated. Reactions were probed with MBP antibody. D, ubiquitination assays containing E1, His6-UbcH5C,
and bovine Ub were performed in the presence or absence of GST-c-IAP1 as indicated. MBP or recombinant wild-type NEMO or mutant zinc finger
proteins were tested. E, ubiquitination assays were performed as described in the legend to C, except that His6-tagged Ub was used. His6-UbcH5C,
His6-UbcH3, His6-UbcH6, UbcH7, His6-UbcH10, or His6-UbcH13 was also included where indicated. F, schematic representation of Ub mutants
used in this study. G, ubiquitination assays were performed using E1, His6-UbcH5C, MBP-NEMO, and GST-c-IAP1 where indicated. His6-tagged
wild-type Ub (WT) or a lysine-less (7R) was tested for conjugation to MBP-NEMO. H, ubiquitination assays were performed with E1, His6-UbcH5C,
His6-Ub, MBP-NEMO, and either wild-type, RING, C605A, or RING GST fusion proteins as indicated. I, ubiquitination assays were performed
with E1, His6-UbcH5C (lanes 2–4 and 6–8), GST-c-IAP1 (lanes 1–4), and GST-ROC1 (lanes 5–8) as shown. His6-tagged wild-type Ub (WT) or the
lysine-less (7R) or K48R mutant were included where indicated. Reactions were probed with Ub antibody. J, ubiquitination assays were performed
with E1, His6-UbcH5C, GST-c-IAP1 (lanes 2–10), and His6-tagged wild-type Ub (WT), lysine-less (7R), or single lysine Ub mutants as indicated.
K, ubiquitination assays were performed with E1, His6-UbcH5C, GST-c-IAP1, and MBP-NEMO where indicated. His6-tagged wild-type Ub (WT),
lysine-less (7R), or single lysine Ub mutants were included as indicated. MBP-NEMO was immunoprecipitated from reactions using anti-NEMO
antibody and probed with Ub antibody.
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was significantly less active in elevating NEMO ubiquitination,
suggesting that other sequences of c-IAP1 were important also.
Thus, the stimulation of NEMO ubiquitination by c-IAP1 is
RING finger-dependent and may depend on the E3 activity of
c-IAP1.
Ubiquitination of NEMO in Vitro by c-IAP1 and UbcH5C—
Next, we investigated whether c-IAP1 might be able to function
as an E3 to ubiquitinate NEMO using purified components in
vitro. In our ubiquitination assay we used rabbit E1 (Ub-acti-
vating enzyme), bovine Ub, and bacterially expressed UbcH5C,
c-IAP1, and NEMO. A UbcH5 family member had been previ-
ously shown to both function as an E2 in conjunction with
c-IAP1 to ubiquitinate proteins (42) and mediate IKK activa-
tion in vitro (34). Inclusion of E1, UbcH5C, and c-IAP1 in
ubiquitination reactions was sufficient to catalyze the ubiquiti-
nation of NEMO (Fig. 3C). Ubiquitination was absolutely de-
pendent on E1, UbcH5C, and c-IAP1 each, because no ubiquiti-
nation was observed when any one of these components was
omitted.
Given that an intact zinc finger in NEMO is required for its
ubiquitination in response to TNF- (Fig. 2B), we examined
whether the zinc finger might be important for ubiquitination
in vitro by c-IAP1. We compared the ubiquitination of wild-type
NEMO and zinc finger mutants by UbcH5C/c-IAP1. Like wild-
type NEMO, both the ZF and C417R mutants were also
ubiquitinated by UbcH5C/c-IAP1, but less efficiently (Fig. 3D).
Thus, an intact zinc finger appears to be important for NEMO
to be efficiently recognized by UbcH5C/c-IAP1 as a substrate
for ubiquitination.
Ubiquitination of NEMO was also observed in reactions
where His6-tagged Ub purified from bacteria was used as a
source of Ub. However, these reactions yielded higher migrat-
ing conjugates than those seen when using bovine Ub, a differ-
ence that may be attributable to the presence of inhibitors of
ubiquitination in the bovine Ub purification (Fig. 3E). To de-
termine whether NEMO was conjugated to polyUb chains in
vitro by UbcH5C/c-IAP1, we tested a lysine-less Ub mutant
(7R) in which all 7 Lys residues are replaced by Arg residues
(Fig. 3F). In contrast to wild-type Ub, the 7R mutant cannot be
used to extend a polyUb chain. Reactions using wild-type Ub
contained higher molecular weight conjugates not seen when
using the 7R mutant, suggesting that NEMO-polyUb conju-
gates were assembled (Fig. 3G). The ability of UbcH5C to
catalyze polyubiquitination of NEMO was specific among sev-
eral E2 enzymes that were tested (Fig. 3E). Also, unlike c-IAP1,
the other RING finger E3s ROC1 and HDM2 failed to polyu-
biquitinate NEMO under similar conditions (data not shown).
As expected, the ability of c-IAP1 to function as an E3 was
absolutely dependent on its RING finger, because deletion of
the RING finger (RING) or substitution of Cys 605 with Ala
(C605A) rendered c-IAP1 inactive in ubiquitinating NEMO
(Fig. 3H). The RING finger alone could also promote polyubiq-
uitination, albeit less effectively than wild-type c-IAP1. We
have found previously that the ROC1 RING finger alone is
sufficient to activate UbcH5C in catalyzing polyubiquitin
chains (44). Our results here suggest that the c-IAP1 RING
finger may function in a similar manner. Taken together with
our observation that the RING finger alone is also less effective
than full-length NEMO in stimulating ubiquitination in vivo
(see Fig. 3B), it appears that sequences outside of the c-IAP1
RING finger are required for optimal substrate ubiquitination,
perhaps by serving as a NEMO binding site (see below).
Ubiquitination of NEMO by Non-Lys48-linked PolyUb
Chains—Most protein ubiquitination studied to date involves
the conjugation of Lys48-linked polyUb chains to proteins, lead-
ing to their subsequent recognition and degradation by the
proteasome. Given our findings that ubiquitinated NEMO is
not targeted for degradation, we examined the polyUb chains
assembled by c-IAP1 in more detail. ROC1 is a RING finger
protein that is a component of the multisubunit E3 SCF com-
plex that targets proteins such as IB and -catenin for deg-
radation. We found previously that ROC1 alone is sufficient to
FIG. 3—continued
Role for NEMO Ubiquitination in IKK Activation 37301
function as an E3 with UbcH5C to catalyze polyUb chains (44).
When c-IAP1 and ROC1 were tested for their abilities to func-
tion as E3s in in vitro assays, we found that Lys48 in Ub was
required for polyUb assembly by ROC1 but not by c-IAP1 (Fig.
3I). Thus, the identity of the particular RING finger E3 can
dictate the structure of the polyUb chains that can be assem-
bled in conjunction with UbcH5C.
Further experiments using single lysine Ub mutants (Fig.
3F) demonstrated that c-IAP1 could specifically assemble Lys
6-linked polyUb chains (Fig. 3J). When NEMO was included as
a substrate, c-IAP1/UbcH5C was found to be able to catalyze
the modification of substrate by Lys6-linked polyUb chains
(Fig. 3K). Of note, the assembly of Lys6-linked chains was
noticeably less efficient than the assembly of wild-type polyUb
chains (Fig. 3J). This disparity can likely be attributed to the
effect of the six lysine to arginine substitutions on protein
structure. However, we cannot rule out the possibility from
these experiments that other lysines in Ub other than Lys6 can
also be used in polyUb chains.
Role of c-IAP1 in IKK Activation by TNF-—Given the ability
of c-IAP1 to stimulate NEMO ubiquitination, we wanted to
examine if c-IAP1 could stimulate NF-B activity as well. Over-
expression of c-IAP1 in cells was able to activate NF-B and
this activity was dependent on the RING finger of c-IAP1 (Fig.
4A). Expression of the c-IAP1 RING finger mutants RING and
C605A had varying effects on NF-B activation by TNF-, with
the latter mutant having a more potent dominant interfering
effect (Fig. 4A). Also, the ability of c-IAP1 to activate NF-B
was dependent on the presence of NEMO, as suggested in
experiments with NEMO-deficient cells (Fig. 4B). When coex-
pressed in 293T cells, c-IAP1 and NEMO could coimmunopre-
cipitate together (Fig. 4C). Endogenous c-IAP1 and NEMO
were also found to associate together in HeLa cells in a stim-
ulus-independent manner (Fig. 4D). Past reports have sug-
FIG. 4. TNF--stimulated IKK activation and NEMO ubiquitination are mediated by c-IAP1 in vivo. A, 293T cells were transfected with
pNF-B-luciferase, pCMV--galactosidase, and pcDNA3 (vector) or FLAG-tagged wild-type and mutant c-IAP1 proteins as indicated. 24 h following
transfection, extracts were analyzed for luciferase activity. Results were normalized to -galactosidase activity readings. Where indicated, TNF-
(10 ng/ml) was added 6 h prior to extract preparation. Samples were performed in duplicate and results shown are representative of three
independent experiments. B, NEMO-deficient JM4.5.2 cells were transiently transfected with HA-NEMO and FLAG-c-IAP1 or FLAG-c-
IAP1(C605A) where indicated along with pNF-B-luciferase and pCMV--galactosidase. 48 h after transfection, cell extracts were prepared and
analyzed for luciferase activity as described in the legend to C. C, HA-NEMO and Myc-c-IAP1 were coexpressed in 293T cells as indicated. Anti-Myc
immunoprecipitates were separated by SDS-PAGE and immunoblotted with HA antibody. D, HeLa cells treated or untreated with 10 ng/ml of
TNF- for 10 min were lysed and immunoprecipitates prepared using the antibodies indicated. Immunoprecipitates were separated by SDS-PAGE
and immunoblotted with NEMO antibody. E, the horizontal bars signify the sequence of c-IAP1 with BIR domains and RING finger (RG) indicated.
The interactions between Myc-tagged wild-type and mutant c-IAP1 with FLAG-TRAF2 and HA-NEMO were discerned by coimmunoprecipitation
assays in 293T cells. A plus sign indicates that an interaction was seen, while a minus sign indicates that an interaction was not detected. Protein
expression was confirmed by immunoblotting of cellular lysates. F, HA-NEMO was coexpressed with FLAG-TRAF2 and Myc-c-IAP1 or Myc-c-
IAP1121 in 293T cells where indicated. Anti-HA immunoprecipitates were examined as described in the legend to E using HA or FLAG antibody.
G, 293T cells transfected with empty vector (pTKO) or an c-IAP1 siRNA expression plasmid were selected for using puromycin. Whole cell extracts
were probed with c-IAP1, c-IAP2 (R&D Systems), or XIAP (BD Transduction Laboratories) antibodies. H, 293T cells transfected with empty vector
(pTKO), a c-IAP1 siRNA expression plasmid (c-IAP1 RNAi), or control siRNA plasmid (TRAF6 RNAi) were selected for using puromycin and
treated with TNF- (10 ng/ml) where indicated. Anti-NEMO immunoprecipitates were assayed for IKK activity (top) or probed for IKK subunits
by immunoblotting (bottom) using IKK (Santa Cruz Biotechnology, H-744), IKK (BD Transduction Laboratories), or NEMO antibodies. I, 293T
cells transfected empty vector (lanes 1 and 2) or Myc-c-IAP1(C605A) (lanes 3 and 4) and FLAG-IKK (lanes 1–4) were lysed, and anti-FLAG
immunoprecipitates were assayed for IKK activity (top) or FLAG-IKK protein. J, 293T cells transfected with pTKO or c-IAP1 siRNA expression
plasmid were selected for using puromycin, and anti-NEMO immunoprecipitates were probed using Ub or NEMO antibodies. Also, lysates were
examined for phosphorylated IB or total IB protein.
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gested that c-IAP1 is recruited to the receptor complex by
binding to TRAF2 (39, 45). We compared the abilities of TRAF2
and NEMO to bind to several deletion mutants of c-IAP1 in
transient transfection assays. These results suggested that
TRAF2 and NEMO bind to distinct domains outside of the
RING finger of c-IAP1 (Fig. 4E). Experiments performed with
these c-IAP1 deletion mutants suggested that both the RING
finger and the ability to bind NEMO were required to activate
NF-B (Fig. 4A). Since TRAF2 directly binds to c-IAP1 and is
required for recruitment of both c-IAP1 and NEMO to the
signaling complex (38, 45), we examined whether c-IAP1 could
bridge an interaction between TRAF2 and NEMO. When
NEMO and TRAF2 were coexpressed in the absence of trans-
fected c-IAP1, a relatively small amount of NEMO was found
bound to TRAF2 (Fig. 4F). However, coexpression of c-IAP1
significantly enhanced the NEMO-TRAF2 interaction. A
c-IAP1 mutant that was defective in binding to TRAF2, but not
NEMO (121), (see Fig. 4E) failed to increase the interaction.
Thus, c-IAP1 may mediate the recruitment of NEMO to TRAF2
and the TNFR1 signaling complex as well as regulate NEMO
ubiquitination.
To see whether endogenous c-IAP1 was required for IKK
activation by TNF-, we used RNAi to deplete endogenous
c-IAP1. We examined the TNF- response of 293T cells that
were transfected with a hairpin siRNA expression plasmid that
reduces the expression of c-IAP1 but did not effect the expres-
sion of the related proteins c-IAP2 or XIAP (Fig. 4G). Cells
transfected with the c-IAP1 siRNA plasmid displayed impaired
IKK activation and IB phosphorylation in response to TNF-
(Fig. 4, H and J). Expression of the RING finger C605A mutant
of c-IAP1 was able to function as a dominant interfering mu-
tant in suppressing IKK activation as well (Fig. 4I). Further-
more, cells transfected with the c-IAP1 siRNA plasmid dis-
played impaired the ubiquitination of endogenous NEMO in
response to TNF-, suggesting that NEMO ubiquitination is
mediated by c-IAP1 in vivo (Fig. 4J). Of note, we did not find
any differences in rates of apoptosis between cells transfected
with c-IAP1 siRNA plasmid and control cells (data not shown).
These data together suggest an important role for c-IAP1 in
mediating both IKK activation and NEMO ubiquitination in
response to TNF-.
Requirement of the NEMO Zinc Finger in TNF--induced
IKK Activation—Given that cells from patients with HED-ID
have been reported to display defective NF-B signaling (29,
30), we sought to determine whether the NEMO zinc finger was
important for TNF--induced NF-B activation. We compared
the functional activities of wild-type NEMO and zinc finger
mutants in JM4.5.2 cells, a T cell line that lacks expression of
NEMO (46). These cells have been previously shown to be
defective in activating NF-B in response to phorbol 12-myris-
tate 13-acetate/ionomycin or the retroviral oncoprotein Tax (46,
47). JM4.5.2 cells also failed to activate NF-B in the response
to TNF-, and this defect was restored by the expression of
wild-type NEMO (Fig. 5A). In contrast, both zinc finger NEMO
mutants, ZF and C417R, demonstrated impaired abilities to
restore the activation of an NF-B luciferase reporter by
TNF-, suggesting that an intact zinc finger is important for
NF-B activation (Fig. 5A).
To examine the importance of the NEMO zinc finger in IKK
function, we stably expressed wild-type NEMO or the C417R
FIG. 4—continued
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mutant in JM4.5.2 cells by retroviral infection. As expected, the
C417R mutant displayed defective TNF--stimulated ubiquiti-
nation when compared with wild-type NEMO (Fig. 5B). Signif-
icantly, we found that in contrast to wild-type NEMO, the
C417R mutant was unable to restore TNF--induced phospho-
rylation of IB (Fig. 5C). The activation of IKK was also not
restored (Fig. 5D), even though IKK complexes displayed sim-
ilar levels of IKK, IKK, and NEMO proteins (data not
shown). Thus, the zinc finger of NEMO is necessary for proper
IKK activation, but not for its incorporation into the IKK com-
plex. Furthermore, wild-type, but not mutant, NEMO protein
could restore TNF--induced phosphorylation of IKK on
Ser181 in its activation loop (Fig. 5D). The defect in restoring
NF-B activation by the NEMO mutants can therefore be at-
tributed to defective IKK phosphorylation and activation in
these cells.
In summary, our results suggest that the conserved zinc
finger of NEMO is required for both NEMO ubiquitination and
IKK activation by TNF-. The inhibitor of apoptosis protein
c-IAP1, which is recruited to the TNF receptor complex, is an
important mediator of IKK activation and NEMO ubiquitina-
tion in response to TNF-. Thus, NEMO ubiquitination by
c-IAP1 appears to be a critical event in the activation of IKK in
response to TNF-. In addition, our data from in vitro Ub
assays suggest that the identity of the RING finger E3 can
dictate the lysine of Ub that is used in the polyUb chains that
are assembled. A recent report found that mutation of two
cysteines in the zinc finger of NEMO distinct from Cys417
impaired TNF--induced, but not IL-1-induced, IKK activation
in mouse embryonic fibroblasts (32). These results are in ac-
cordance with our findings, and together with our data suggest
that NEMO ubiquitination by c-IAP1 plays a specific role in
TNF- signaling.
Interestingly, previous work described the identification of a
purified IKK complex that could be activated by a ubiquitina-
tion event involving a UbcH5 family member and an unidenti-
fied factor (34). Based on our findings, c-IAP1 may be this
unidentified factor, and NEMO may be the target for ubiquiti-
nation. TRAF2 is another E3 that plays an important role in
IKK activation in response to TNF- (38). Unlike, c-IAP1,
TRAF2 does not appear to mediate NEMO ubiquitination.
TRAF2 may instead play a role upstream of IKK activation in
FIG. 5. The NEMO zinc finger is required for IKK activation by TNF-. A, the NEMO-deficient JM4.5.2 cell line was transiently
transfected with pNF-B-luc, pCMV--galactosidase, and pcDNA3 (vector) or HA-tagged wild-type NEMO (WT), ZF mutant, or C417R mutant
as indicated. 40 h following transfection, cells were stimulated with TNF- (10 ng/ml) for 8 h (lanes 5–8) or untreated (lanes 1–4) and lysed.
Extracts were assayed for luciferase activity as in Fig. 4A. The results shown are the average of three independent experiments. B, stably infected
JM4.5.2 cells expressing wild-type NEMO or the C417R mutant were untreated or treated with TNF- (10 ng/ml) for 5 min. Lysates from 5  106
cells were prepared, and anti-NEMO immunoprecipitates were analyzed as described in the legend to Fig. 1B using Ub or NEMO antibodies. C,
stably infected JM4.5.2 cells were untreated or treated with TNF- (10 ng/ml) for 5 min. Lysates prepared from 5  106 cells stably expressing the
indicated NEMO proteins were prepared and were run out by SDS-PAGE. Immunoblotting was performed with phospho-IB antibody. D, IKK
activity was measured from stably infected JM4.5.2 cells untreated or treated with TNF- (10 ng/ml) for indicated times (top and bottom).
Alternatively, immunoprecipitates were probed with a phospho-IKK antibody (Cell Signaling) (top). Phosphorylation of GST-IB-(1–54) was
analyzed on a phosphoimager, and the intensity of bands was calculated using the Image Quant Microsoft system.
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TNF- signaling by ubiquitinating itself with Lys63-linked
polyUb chains, in a similar mechanism as has been postulated
for TRAF6 in the IL-1 signaling pathway (48–50).
It remains to be determined what the exact role of the NEMO
zinc finger in NEMO ubiquitination and IKK activation is. We
have found that removal of the zinc finger does not affect the
binding of NEMO to c-IAP1.3 It is possible that the zinc finger
may facilitate the assembly of other ubiquitination factors such
as UbcH5C. The ubiquitination of NEMO may in turn lead to
the recruitment of an IKK kinase such as MEKK3 or PKC
( isoform of protein kinase C) (51, 52) to the IKK complex,
thereby leading to IKK phosphorylation and consequently
IKK activation.
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